Pache I, Bize P, Halkic N, Montemurro M, Giostra E, Majno P, Moradpour D
Service de gastro-entérologie et d'hépatologie, CHUV, Lausanne.
Rev Med Suisse. 2010 Jan 27;6(233):198-202.
Hepatocellular carcinoma (HCC) is one of the most frequent malignant tumors worldwide and its incidence has increased over the last years in most developed countries. The majority of HCCs occur in the context of liver cirrhosis. Therefore, patients with cirrhosis and those with hepatitis B virus infection should enter a surveillance program. Detection of a focal liver lesion by ultrasound should be followed by further investigations to confirm the diagnosis and to permit staging. A number of curative and palliative treatment options are available today. The choice of treatment will depend on the tumor stage, liver function and the presence of portal hypertension as well as the general condition of the patient. A multidisciplinary approach is mandatory to offer to each patient the best treatment.
肝细胞癌(HCC)是全球最常见的恶性肿瘤之一,在大多数发达国家,其发病率在过去几年中有所上升。大多数肝细胞癌发生在肝硬化的背景下。因此,肝硬化患者和乙肝病毒感染患者应进入监测程序。通过超声检测到肝脏局灶性病变后,应进行进一步检查以确诊并进行分期。目前有多种根治性和姑息性治疗选择。治疗方法的选择将取决于肿瘤分期、肝功能、门静脉高压的存在以及患者的一般状况。必须采用多学科方法为每位患者提供最佳治疗。